Cargando…
Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
Ginseng, one of the oldest traditional Chinese medicinal herbs, has been used widely in China and Asia for thousands of years. Ginsenosides extracted from ginseng, which is derived from the roots and rhizomes of Panax ginseng C. A. Meyer, have been used in China as an adjuvant in the treatment of di...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938666/ https://www.ncbi.nlm.nih.gov/pubmed/29765322 http://dx.doi.org/10.3389/fphar.2018.00423 |
_version_ | 1783320824771510272 |
---|---|
author | Bai, Litao Gao, Jialiang Wei, Fan Zhao, Jing Wang, Danwei Wei, Junping |
author_facet | Bai, Litao Gao, Jialiang Wei, Fan Zhao, Jing Wang, Danwei Wei, Junping |
author_sort | Bai, Litao |
collection | PubMed |
description | Ginseng, one of the oldest traditional Chinese medicinal herbs, has been used widely in China and Asia for thousands of years. Ginsenosides extracted from ginseng, which is derived from the roots and rhizomes of Panax ginseng C. A. Meyer, have been used in China as an adjuvant in the treatment of diabetes mellitus. Owing to the technical complexity of ginsenoside production, the total ginsenosides are generally extracted. Accumulating evidence has shown that ginsenosides exert antidiabetic effects. In vivo and in vitro tests revealed the potential of ginsenoside Rg1, Rg3, Rg5, Rb1, Rb2, Rb3, compound K, Rk1, Re, ginseng total saponins, malonyl ginsenosides, Rd, Rh2, F2, protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins to treat diabetes and its complications, including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic nephropathy, diabetic cognitive dysfunction, type 2 diabetes mellitus with fatty liver disease, diabetic cerebral infarction, diabetic cardiomyopathy, and diabetic erectile dysfunction. Many effects are attributed to ginsenosides, including gluconeogenesis reduction, improvement of insulin resistance, glucose transport, insulinotropic action, islet cell protection, hepatoprotective activity, anti-inflammatory effect, myocardial protection, lipid regulation, improvement of glucose tolerance, antioxidation, improvement of erectile dysfunction, regulation of gut flora metabolism, neuroprotection, anti-angiopathy, anti-neurotoxic effects, immunosuppression, and renoprotection effect. The molecular targets of these effects mainly contains GLUTs, SGLT1, GLP-1, FoxO1, TNF-α, IL-6, caspase-3, bcl-2, MDA, SOD, STAT5-PPAR gamma pathway, PI3K/Akt pathway, AMPK-JNK pathway, NF-κB pathway, and endoplasmic reticulum stress. Rg1, Rg3, Rb1, and compound K demonstrated the most promising therapeutic prospects as potential adjuvant medicines for the treatment of diabetes. This paper highlights the underlying pharmacological mechanisms of the anti-diabetic effects of ginsenosides. |
format | Online Article Text |
id | pubmed-5938666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59386662018-05-14 Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes Bai, Litao Gao, Jialiang Wei, Fan Zhao, Jing Wang, Danwei Wei, Junping Front Pharmacol Pharmacology Ginseng, one of the oldest traditional Chinese medicinal herbs, has been used widely in China and Asia for thousands of years. Ginsenosides extracted from ginseng, which is derived from the roots and rhizomes of Panax ginseng C. A. Meyer, have been used in China as an adjuvant in the treatment of diabetes mellitus. Owing to the technical complexity of ginsenoside production, the total ginsenosides are generally extracted. Accumulating evidence has shown that ginsenosides exert antidiabetic effects. In vivo and in vitro tests revealed the potential of ginsenoside Rg1, Rg3, Rg5, Rb1, Rb2, Rb3, compound K, Rk1, Re, ginseng total saponins, malonyl ginsenosides, Rd, Rh2, F2, protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins to treat diabetes and its complications, including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic nephropathy, diabetic cognitive dysfunction, type 2 diabetes mellitus with fatty liver disease, diabetic cerebral infarction, diabetic cardiomyopathy, and diabetic erectile dysfunction. Many effects are attributed to ginsenosides, including gluconeogenesis reduction, improvement of insulin resistance, glucose transport, insulinotropic action, islet cell protection, hepatoprotective activity, anti-inflammatory effect, myocardial protection, lipid regulation, improvement of glucose tolerance, antioxidation, improvement of erectile dysfunction, regulation of gut flora metabolism, neuroprotection, anti-angiopathy, anti-neurotoxic effects, immunosuppression, and renoprotection effect. The molecular targets of these effects mainly contains GLUTs, SGLT1, GLP-1, FoxO1, TNF-α, IL-6, caspase-3, bcl-2, MDA, SOD, STAT5-PPAR gamma pathway, PI3K/Akt pathway, AMPK-JNK pathway, NF-κB pathway, and endoplasmic reticulum stress. Rg1, Rg3, Rb1, and compound K demonstrated the most promising therapeutic prospects as potential adjuvant medicines for the treatment of diabetes. This paper highlights the underlying pharmacological mechanisms of the anti-diabetic effects of ginsenosides. Frontiers Media S.A. 2018-05-01 /pmc/articles/PMC5938666/ /pubmed/29765322 http://dx.doi.org/10.3389/fphar.2018.00423 Text en Copyright © 2018 Bai, Gao, Wei, Zhao, Wang and Wei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Bai, Litao Gao, Jialiang Wei, Fan Zhao, Jing Wang, Danwei Wei, Junping Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes |
title | Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes |
title_full | Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes |
title_fullStr | Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes |
title_full_unstemmed | Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes |
title_short | Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes |
title_sort | therapeutic potential of ginsenosides as an adjuvant treatment for diabetes |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938666/ https://www.ncbi.nlm.nih.gov/pubmed/29765322 http://dx.doi.org/10.3389/fphar.2018.00423 |
work_keys_str_mv | AT bailitao therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes AT gaojialiang therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes AT weifan therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes AT zhaojing therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes AT wangdanwei therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes AT weijunping therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes |